Straight Talk with the Expert Surrounding COVID-19 and Your Patients with ILD
| Overview / Abstract: |
Dr. Imre Noth summarizes what we have learned through August 2020 about COVID-19 and its implications for patients with interstitial lung disease (ILD) while providing his own front-line clinical experiences. Talking points include mitigating risks of COVID-19 in patients with ILD, strategies to help patients continue ILD treatment and supportive care, as well as strategies to differentiate post-ARDS fibrosis and ILDs. This activity is intended for primary care providers, pulmonologists, respiratory therapists, nurse practitioners, and physician assistants who treat patients with ILD. Upon completion of the educational activity, participants should be able to: |
|
Expiration |
Sep 09, 2021 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME, Respiratory Therapy CE |
|
Format |
Online, Podcast, Webinar / Webcast / Video |
|
Credits / Hours |
0.5 |
|
Accreditation |
ACCME |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Imre Noth, MD |
|
Activity Specialities / Related Topics |
Critical Care / Intensive Care, Education / Teaching, Emergency Medicine, Infectious Disease, Internal Medicine, Preventive Care, Primary Care, Pulmonary Medicine / COPD |
|
Sponsors / Supporters / Grant Providers |
Supported by educational grants from Boehringer Ingelheim Pharmaceuticals and Genentech, Inc. |
|
Keywords / Search Terms |
ACHL COVID-19, COVID, coronavirus, ILD, interstitial lung disease, fibrosis, ARDS, acute respiratory disease syndrome, differential, diagnosis, telemedicine, risk, pandemic, fibrotic, lung, infection, infections, dexamethasone, remdesivir, Decadron, SARS-CoV-2, nintedanib, pirfenidone, Ofev, Esbriet Free CE CME Live CE CME |
|